Abstract
1049Background: Compared to placebo (P) + fulvestrant (F), the MONARCH 2 HR+, HER2- ABC trial showed abemaciclib + F significantly improved PFS and ORR with a generally tolerable safety profile. He...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
